A fluorescent composite, HCAA@UiO-66, was prepared by encapsulating fluorescent 7-hydroxycoumarin-4-acetic acid (HCAA) molecules into pore of metal-organic framework (MOF, UiO-66). The encapsulating of HCAA in the pore of UiO-66 does...

CdSe/CdS quantum dots (QDs) capped with L-cysteine can provide an effective platform for the interactions with bovine serum albumin (BSA). In this study, absorption and fluorescence (FL) spectroscopy were used to study the binding reactions of QDs with BSA, respectively. The binding constant (≈10(4) M(-1)) from FL quenching method matches well with that determined from the absorption spectral changes. The modified Stern-Volmer quenching constant (5.23 × 10(4), 5.22 × 10(4), and 4.90 × 10(4) M(-1)) and the binding sites (≈1) at different temperatures (304 K, 309 K, and 314 K) and corresponding thermodynamic parameters were calculated (∆G < 0, ∆H < 0, and ∆S < 0). The results show the quenching constant is inversely correlated with temperature. It indicates the quenching mechanism is the static quenching in nature rather than dynamic quenching. The negative values of free energy (∆G < 0) suggest that the binding process is spontaneous, ∆H < 0 and ∆S < 0 suggest that the binding of QDs to BSA is enthalpy-driven. The enthalpy and entropy changes for the formation of ground state complex depend on the capping agent of QDs and the protein types. Furthermore, the reaction forces were discussed between QDs and BSA, and the results show hydrogen bonds and van der Waals interactions play a major role in the binding reaction.

No abstract

Platinum drugs with manifest therapeutic effects are widely used, but their systemic toxicity and the drug resistance acquired by cancer cells limit their clinical applications. Thus, the exploration on appropriate methods and strategies to overcome the limitations of traditional platinum drugs becomes extremely necessary. Combination therapy of platinum drugs can inhibit tumor growth and metastasis in an additive or synergistic manner, and can potentially reduce the systemic toxicity of platinum drugs and overcome platinum‐resistance. This review summarizes the various modalities and current progress in platinum‐based combination therapy. The synthetic strategies and therapeutic effects of some platinum‐based anticancer complexes in the combination of platinum drugs with gene editing, ROS‐based therapy, thermal therapy, immunotherapy, biological modelling, photoactivation, supramolecular self‐assembly and imaging modality are briefly described. Their potential challenges and prospects are also discussed. It is hoped that this review will inspire researchers to have more ideas for the future development of highly effective platinum‐based anti‐cancer complexes.

No abstract